Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.

People treated for aggressive melanoma now have a concrete reason to watch a single experimental combination closely. In a ...

For most of the past three years, Jim Cramer kept his distance from Moderna, treating the biotech stock with skepticism bordering on avoidance. The Cambridge, Massachusetts, company had become ...

Moderna ( MRNA +10.01%) stock jumped about 10% on Thursday to $79.76 -- a fresh high for the year and the latest leg of a run ...

Shares of Moderna MRNA have surged 33.5% over the past week, adding nearly $8 billion to the company's market value. The ...

Many of the FDA’s decisions this quarter involve applications that have previously been delayed, declined or outright ...

The FDA advisory panel unanimously supported mRNA-1010/mFLUSIVA for adults 50–64 and 65+, and the stock is already reacting ...

To date, the company has raised over $34 million from investors and operates a 15-person team at facilities at Johns Hopkins Medical Campus.

From space to healthcare and artificial intelligence, what could the next 250 years of the United States look like?

A recent survey suggests that using apps and artificial intelligence for health advice may be linked to vaccine distrust.

Moderna shares climbed 13% to reach $67.50 on June 26, tracking toward the strongest close since September 2024 The biotech firm unveiled mRNA-6007, its inaugural in vivo CAR-T initiative, focused on ...

The study also reviews the great potential of mRNA vaccines to treat influenza, RSV, cancer, and autoimmune diseases.